Adaptimmune Therapeutics

Adaptimmune Therapeutics, founded in 2008, is a clinical-stage biopharmaceutical company specializing in the development of novel cancer immunotherapies. The firm utilizes a proprietary T-cell receptor platform to engineer next-generation cell therapies designed to treat various malignancies. By harnessing the power of the immune system, Adaptimmune Therapeutics focuses on delivering off-the-shelf therapeutic candidates that improve patient outcomes in the global healthcare market. Their research efforts are centered on creating biological solutions that address unmet medical needs in oncology, positioning the company as a pioneer in the biotechnology sector.

The organization maintains a robust operational footprint with 500-1,000 employees dedicated to advancing clinical-stage biotechnology. Their workforce includes specialized teams across engineering, scientific research, and medical health sectors, ensuring rigorous development cycles for their pipeline. The company leverages its internal expertise to manage complex clinical trials and regulatory pathways. Meet Adaptimmune Therapeutics's team to learn about the leadership and scientific expertise driving their innovative research and development initiatives, which are supported by a diverse group of professionals focused on operational excellence.

Trading under the ticker NASDAQ: ADAP, the company demonstrates a consistent commitment to growth within the competitive biopharmaceutical landscape. With annual revenue reaching $65.1M, Adaptimmune Therapeutics continues to secure funding and strategic partnerships to support its long-term commercialization goals. The firm competes with major industry players while maintaining a focus on its core therapeutic mission. Explore financial highlights for detailed metrics regarding their fiscal performance and capital structure.